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A novel PTCH1 mutation in a patient with Gorlin syndrome
Nana Okamoto1,5, Takuya Naruto2,5, Tomohiro Kohmoto3, Takahide Komori1 and Issei Imoto4
Gorlin syndrome is an autosomal dominant disorder characterized by a wide range of developmental abnormalities and a
predisposition to various tumors, and it is linked to the alteration of several causative genes, including PTCH1. We performed targeted
resequencing using a next-generation sequencer to analyze genes associated with known clinical phenotypes in an 11-year-old male
with sporadic jaw keratocysts. A novel duplication mutation (c.426dup) in PTCH1, resulting in a truncated protein, was identified.
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Basal cell nevus syndrome (BCNS; MIM #109400) or Gorlin
syndrome,1 also known as nevoid basal cell carcinoma syndrome
(NBCCS) or Gorlin–Goltz syndrome, is a rare autosomal dominant
disorder with almost 100% penetrance and variable expressivity.
Gorlin syndrome is characterized by a wide range of develop-
mental abnormalities and a predisposition to neoplasms. Muta-
tions in the PTCH1 gene (MIM #601309) are the main molecular
defects associated with Gorlin syndrome,2,3 although mutations in
other genes involved in the hedgehog pathway, such as PTCH2
(MIM #603673) and SUFU (MIM #607035),4,5 have also been
reported in patients with this syndrome. Here, we report a novel
PTCH1 gene duplication mutation (c.426dup) that was detected in
a patient with a history of multiple keratocystic odontogenic
tumors (KCOTs, Figure 1a) of the jaw, which is the most consistent
and common manifestation of Gorlin syndrome.6
An 11-year-old Chinese male with no family history of
consanguinity presented to our clinic with plantar pits
(Figure 1b), mild macrocephaly, a coarse face and melanotic
macules. His psychomotor development was appropriate for his
age, and the results of neurological and ophthalmological
examinations were normal. Imaging tests (magnetic resonance
imaging and orthopantomography) revealed multiple odonto-
genic cysts (Figure 1a). A radiograph of the skull revealed
bilamellar calcifications of the falx cerebri and bulging of the
sella turcica (Figure 1c). Histopathological examination of the
odontogenic cysts confirmed the diagnosis of KCOTs. Over 2 years
of follow-up, new black pit lesions appeared on his right cheek.
However, neither basal cell carcinoma nor bifid, fused or markedly
splayed ribs were observed.
On the basis of the presence of three major criteria for clinical
diagnosis,7 the patient was diagnosed with Gorlin syndrome. The
molecular diagnosis was performed using genomic DNA extracted
from the patient’s whole blood after obtaining informed consent.
The study was approved by the ethical committees of Kobe
University and The University of Tokushima. Because various
alterations, including mutations and copy number alterations
(CNAs)8 of three genes with numerous exons (PTCH1, PTCH2 and
SUFU) can be responsible for Gorlin syndrome, we first used a
Miseq bench-top sequencer (Illumina, San Diego, CA, USA) to
perform next-generation sequencing with a TruSight One
Sequencing Panel (Illumina) for the simultaneous targeted
sequencing of the exon regions of 4,813 clinically relevant genes.
The sequencing reads were aligned to the human reference
genome (hg19) using Burrows–Wheeler aligner (BWA, version
0.7.8; http://bio-bwa.sourceforge.net/).9 The alignments were
converted from a sequence alignment map (SAM) format to a
sorted and indexed binary alignment map files (SAMtools version
0.1.19; http://samtools.sourceforge.net). Duplicate reads were
removed using Picard (http://picard.sourceforge.net). Local rea-
lignment around the indels, base quality score recalibration and
UnifiedGenotyper calls were performed using Genome Analysis
Toolkit software (GATK, version 3.1-1; http://www.broadinstitute.
org/gatk/).10 All sequence variants were annotated using
Annovar.11 To identify single-nucleotide variations, we excluded
sequence variants with minor allele frequency 40.05 from the
1000 Genomes Project databases (http://www.1000genomes.org/),
NHLBI GO Exome Sequencing Project (ESP6500, http://evs.gs.
washington.edu/EVS/) and the Human Genetic Variation Database
(HGVD, http://www.genome.med.kyoto-u.ac.jp/SnpDB/). To com-
plement the single-nucleotide variations and indel analyses, a CNA
detection algorithm was applied to the alignment map files to
identify large CNAs as follows: (1) binary alignment map files were
converted into files covering target regions using GATK, (2) log
coverage ratios and Z scores were calculated between the case
and other samples and (3) regions with an abnormal copy number
were detected using circular binary segmentation with DNAcopy
(R/Bioconductor; http://bioconductor.org).12 These analyses iden-
tified one heterozygous frameshift mutation NM_000264.3
(PTCH1_v001):c.426dup in exon 3 of the PTCH1 gene, which
caused a frameshift at codon 143, resulting in the introduction of a
stop codon at position 155 (NM_000264.3 (PTCH1_i001):p.
(Thr143Tyrfs*12)). This resulted in the loss of most of the coding
region, which resulted in a loss of protein function; thus, this
mutation is the disease-causing alteration in our patient. No other
alterations, including CNAs, were observed around the three
genes. The alteration was then confirmed using PCR-based direct
Sanger sequencing with a BigDye Terminator v3.1 Cycle Sequen-
cing Kit (Applied Biosystems, Foster City, CA, USA) on a 3130
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Figure 1. (a) Dental orthopantomography of a patient affected by multiple keratocystic odontogenic tumors (KCOTs). (b) Numerous tiny black
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Figure 2. Electropherogram of the PTCH1 exon 3 sequence showing the heterozygous germline duplication of a thymine (T) in the patient
DNA. The DNA and corresponding amino-acid sequences of wild-type and mutant PTCH1 alleles are also shown. The affected transcript and
protein were labeled NM_000264.3 (PTCH1_v001):c.426dup and NM_000264.3 (PTCH1_i001):p.(Thr143Tyrfs*12), respectively, using the Human
Genome Variation Society (HGVS) nomenclature version 2.0 (Mutalyzer 2.0.beta-32, https://mutalyzer.nl/). The arrow indicates the
duplication point.
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Genetic Analyzer (Applied Biosystems) in both directions (Figure 2,
primer information is available on request). This mutation has not
been previously reported in any patients with Gorlin syndrome
(Human Gene Mutation Database professional 2014.2, http://www.
hgmd.org/ and ClinVar, http://www.ncbi.nlm.nih.gov/clinvar/) and
is not present in the 1000 Genomes, ESP6500 or HGVD databases.
Because parental DNA was not available, this mutation could not
be confirmed to be de novo.
The human PTCH1 gene contains 23 coding exons that span
~ 70 kb and encode a protein composed of 1,447 amino acids with
12 transmembrane-spanning domains and two large extracellular
loops.3 PTCH1 is the ligand-binding component of the sonic
hedgehog receptor complex. Aberrant activation of the sonic
hedgehog signaling cascade owing to haploinsufficiency of PTCH1
is believed to cause Gorlin syndrome.13 As germline mutations of
PTCH1 in patients with Gorlin syndrome were first reported by two
groups in 1996,2,3 4300 different mutations covering almost all
exons, with no hot spots and various CNAs, have been reported.
Most of these are frameshift or nonsense mutations that lead to
the synthesis of a truncated protein. In a series of 313 PTCH1
mutations reported in the Human Gene Mutation Database, most
of which were detected in cases of Gorlin syndrome, 33.9% were
missense or nonsense mutations, 47.6% were small insertions
and/or deletions and 8.3% were gross deletions, insertions or
duplications. In the current study, we reported a novel germline
duplication (insertion) mutation of PTCH1, c.426dup, in a Chinese
patient with sporadic Gorlin syndrome. This mutation created a
premature termination codon in the mutant allele that resulted in
the truncation of PTCH1. This truncation of PTCH1 is one of the
shortest forms reported to date; this truncation lacks 11 of the
12 transmembrane-spanning domains. Because a premature
termination codon leads to mRNA degradation via nonsense-
mediated mRNA decay,14 the haploinsufficiency of PTCH1 likely
had an important etiological role in this case.
A combination of clinical and molecular screening tools could
be useful for the identification of Gorlin syndrome in patients who
were previously diagnosed with multiple KCOTs of the jaw. These
patients could be identified by retrospectively evaluating the
pathological records.15 Although this case presented with several
symptoms that fulfilled the criteria for the diagnosis of Gorlin
syndrome, identifying the specific pathogenic mutation is useful
for genetic counseling. Therefore, a proper diagnosis is essential,
particularly during the early stages of life. Gorlin syndrome is
primarily caused by mutations in PTCH1. However, no hot-spot
mutations within the 23 coding exons have been reported in this
gene; CNAs are also known to be responsible for Gorlin syndrome.
Genetic alterations in PTCH2 (22 coding exons) and SUFU
(12 coding exons) have also been identified, although they are
rarely observed. Previous studies have revealed that there were no
genotype–phenotype correlations between mutations in PTCH1
or other genes and the major clinical features of Gorlin
syndrome.16,17 Target resequencing of the possible disease-
causing genes and other genes associated with various known
clinical phenotypes using next-generation sequencing technology
enables the simultaneous evaluation of mutations and CNAs.
Therefore, this could form a simple, efficient and economical
genetic test for Gorlin syndrome.
HGV DATABASE
The relevant data from this Data Report are hosted at the
Human Genome Variation Database at http://dx.doi.org/10.6084/
m9.figshare.hgv.513.
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